- ALX Oncology Announces Encouraging Final Results from Ph 1 Trial of Evorpacept + SOC Treatment in Patients with B-cell NHL
- Boehringer’s new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
- Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042
- BriaCell Presents Survival and Clinical Benefit from Ph 2 of Bria-IMT in metastatic breast cancer
- Coherus Presents Promising Early Clinical Data from Ph 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic SCCHN
- EpimAb Biotherapeutics Announced Clinical results for EMB-01 in CRC
- HUTCHMED announced new and updated data from several studies of savolitinib, fruquintinib and surufatinib
- ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML
- KEYTRUDA as Perioperative Treatment With SOC Adjuvant Therapy Significantly Improved EFS Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
- Medicenna Presents Results from the ABILITY-1 Clinical Trial
- PDS Biotech Announces PDS01ADC Clinical Data
- OBI Pharma Announces Poster Presentations for OBI-992 and OBI-902 ADCs, GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
- Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant NSCLC
- Senti Bio’s SENTI-202 Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
- Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma
- Sutro Biopharma Highlighted Next-Generation Exatecan and Dual-Payload ADC Programs
- Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy
- Zymeworks Presents New Data from Multiple Development Programs
